Relation between signs and symptoms in Paget's disease of bone
- PMID: 3714967
Relation between signs and symptoms in Paget's disease of bone
Abstract
The relation between signs and symptoms of Paget's disease of bone was studied in 180 patients consecutively submitted for treatment. In these patients 826 lesions were identified by scintigraphy. The intensity of scintigraphic uptake was correlated with long-term calcium uptake in bone. The frequency distribution of lesions over the patients was compatible with a 65 per cent chance of local disease once the patient had been exposed to an extraneous agent. The spatial distribution within a skeleton was related to the local density of the osteoclast population. The particular frequency distribution resulted in a log-normal distribution diagram for anatomical spread. Within lesions, increases in numbers of osteoclasts and osteoblasts were proportional and these too had a log-normal distribution. Increases of alkaline phosphatase levels and hydroxyproline excretion were closely related and reflected anatomical spread on the one hand and local activity on the other. They were also closely correlated with overall calcium fluxes. It was shown that alkaline phosphatase is the more sensitive and hydroxyproline the more accurate of the biochemical signs. Maximum values, corresponding to total skeletal disease, were approximately 25 times the upper limit of normal. Equilibrium between bone formation and resorption was not always maintained. There were, indeed, wide variations of urinary calcium, which were significantly related to the difference between bone formation and resorption, but the extracellular calcium homeostasis was generally maintained. This may explain the frequent occurrence of normocalcaemic and hypercalcaemic hyperparathyroidism. The hypercalciuria constitutes an additional risk for urolithiasis in men. The most frequent complaint was pain (86 per cent). Extent of lesions was important, but a major decisive factor was the specific nature of the bone affected. The findings allowed assessment of the relative importance of the various signs, symptoms and locations as criteria of disease severity and as indications for treatment.
Similar articles
-
Skeletal distribution and biochemical parameters of Paget's disease.Clin Orthop Relat Res. 1987 Apr;(217):37-44. Clin Orthop Relat Res. 1987. PMID: 3103964
-
Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.Nucl Med Commun. 1999 Jun;20(6):525-8. doi: 10.1097/00006231-199906000-00006. Nucl Med Commun. 1999. PMID: 10451864
-
[Skeletal distribution and biological markers of Paget's disease].Rev Prat. 1989 Apr 27;39(13):1125-8. Rev Prat. 1989. PMID: 2786643 French.
-
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).Clin Orthop Relat Res. 1977;(127):94-105. Clin Orthop Relat Res. 1977. PMID: 410576 Review. No abstract available.
-
Skeletal blood flow in Paget's disease of bone.Metab Bone Dis Relat Res. 1981;3(4-5):263-70. doi: 10.1016/0221-8747(81)90042-4. Metab Bone Dis Relat Res. 1981. PMID: 6762483 Review.
Cited by
-
Epidemiology of Paget's disease of bone in South Korea.JBMR Plus. 2024 Dec 28;9(3):ziae171. doi: 10.1093/jbmrpl/ziae171. eCollection 2025 Mar. JBMR Plus. 2024. PMID: 39906256 Free PMC article.
-
Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.J Bone Miner Metab. 2015 Sep;33(5):584-90. doi: 10.1007/s00774-014-0623-5. Epub 2014 Oct 16. J Bone Miner Metab. 2015. PMID: 25319558
-
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1301-5. doi: 10.1136/bmj.295.6609.1301. Br Med J (Clin Res Ed). 1987. PMID: 3120987 Free PMC article.
-
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs. 1991 Feb;41(2):289-318. doi: 10.2165/00003495-199141020-00009. Drugs. 1991. PMID: 1709854 Review.
-
Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs. 1994 Jun;47(6):945-82. doi: 10.2165/00003495-199447060-00007. Drugs. 1994. PMID: 7521833 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical